The most commonly occurring urologic malignancies include prostate, bladder and kidney
cancer. While prostate cancer is diagnosed in males, bladder and kidney cancer are more …

Our network meta-analysis demonstrates that sRCC are responsive to immune-based
combinations. The dual ICI with nivolumab plus ipilimumab improved all efficacy outcomes …

Introduction: Non-clear cell renal cell carcinoma (nccRCC) represents a highly
heterogenous group of kidney cancer entities. As most clinical trials predominantly include …

Background Collecting duct carcinoma and sarcomatoid renal cell carcinoma are tumors
with poor prognosis. Immune checkpoint inhibitors have been established as the standard …

Objective: to evaluate the risk of treatment-related adverse events of different severity and
different system with PD-1 or PD-L1 inhibitors. Methods: randomized controlled trials (RCTs) …

Cancer is the second leading cause of death worldwide responsible for about 10 million
deaths per year. To date several approaches have been developed to treat this deadly …

Background Lymphatic metastasis is an important mechanism of renal cell carcinoma (RCC)
dissemination and is an indicator of poor prognosis. Therefore, we aimed to identify …

Targeted therapeutics made significant advances in the treatment of patients with advanced
clear cell renal cell carcinoma (ccRCC). Resistance and serious adverse events associated …

The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the
approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine …

Despite attempts to apply single therapy such as surgical treatment, chemotherapy, or
radiotherapy, pancreatic cancer (PC) is still one of the most lethal solid tumors. Moreover …